cyclophosphamide + liposomal doxorubicin + dexamethasone

CDD is a combination chemotherapy regimen consisting of cyclophosphamide, liposomal doxorubicin, and dexamethasone. It is primarily investigated for the treatment of plasma cell dyscrasias, specifically relapsed or refractory multiple myeloma complicated by extramedullary plasmacytoma. Cyclophosphamide is an alkylating agent that works by cross-linking DNA, thereby inhibiting DNA replication and cell division. Liposomal doxorubicin is an anthracycline topoisomerase II inhibitor that intercalates into DNA and inhibits RNA synthesis, delivered in a liposomal formulation to improve its safety profile and tumor targeting. Dexamethasone is a potent synthetic glucocorticoid that exerts anti-inflammatory and immunosuppressive effects while inducing apoptosis in hematologic malignancies. This specific regimen has been studied by Beijing Chao Yang Hospital in Phase 3 clinical trials to evaluate its efficacy as a standalone therapy or in combination with proteasome inhibitors like bortezomib.

Other names

CDD regimenCyclophosphamide, Liposome doxorubicin and DexamethasoneCDD-Beijing Chao Yang Hospital-extramedullary plasmacytoma